Januvia (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Date: July 31, 2013
Pages: 46
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: J268C73EA90EN

Download PDF Leaflet

Januvia (Type 2 Diabetes) - Forecast and Market Analysis to 2022
Januvia (Type 2 Diabetes) - Forecast and Market Analysis to 2022


GlobalData has released its new report, “Januvia (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Januvia (sitagliptin) was approved in 2006, and was the first new oral medication for diabetes in more than a decade, and the first medicine approved by the FDA to inhibit the enzyme DPP-4. Januvia is a once-daily oral tablet, developed by Merck, that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise.

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Januvia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Januvia for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Januvia performance
  • Obtain sales forecast for Januvia from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)

1.1 List of Tables
1.2 List of Figures


2.1 Catalyst
2.2 Related Reports


3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
  3.1.3 Prognosis
  3.1.4 Quality of Life
3.2 Symptoms


4.1 Treatment Overview
  4.1.1 Diagnosis and Referrals
  4.1.2 Treatment Guidelines


5.1 Overview
5.2 Strategic Competitor Assessment


6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast


7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
  7.4.1 Diagnosed Type 2 Patients
  7.4.2 Percent Drug-Treated Patients
  7.4.3 Drugs Included in Each Therapeutic Class
  7.4.4 Launch and Patent Expiry Dates
  7.4.5 General Pricing Assumptions
  7.4.6 Individual Drug Assumptions
  7.4.7 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 About the Authors
  7.6.1 Analyst II - CVMD
  7.6.2 Therapy Director - CVMD and Infectious Disease
  7.6.3 Global Head of Healthcare
7.7 About GlobalData
7.8 Disclaimer


Table 1: Symptoms of Type 2 Diabetes
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes
Table 3: Treatment Guidelines for Type 2 Diabetes
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012
Table 6: Product Profile - Januvia
Table 7: Januvia SWOT Analysis, 2012
Table 8: Global Sales Forecasts ($m) for Januvia and Janumet, 2012-2022
Table 9: Key Launch Dates
Table 10: Key Patent Expiry Dates
Table 11: Number of High-Prescribing Physicians Surveyed


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy
Skip to top

Ask Your Question

Januvia (Type 2 Diabetes) - Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: